Association of Defective Regulation of Autoreactive Interleukin‐6–Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis
- 6 February 2018
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 70 (3) , 450-461
Abstract
Systemic Sclerosis (SSc) has the highest case-specific mortality of any rheumatic disease and has no effective therapy. A clear manifestation of SSc is the presence of auto-antibodies. However, the origin of autoantibody-producing B lymphocytes and mechanisms of their activation, auto-antibody production and role remain unclear. To identify mechanisms that contribute to pathogenic B cell generation, involvement in SSc and assess the altered distribution and function of B cells in patients. Multi-colour flow cytometry was used to determine B cell subset distribution, cytokine production and tolerance induction in SSc patients and healthy controls. Cytokine production following stimulation of the cells ex vivo was carried out by multiplex analysis. The study reveals a range of defects in B lymphocyte tolerance and cytokine production in SSc. Evidence is provided for altered distribution of transitional B cell subsets, increased production of IL-6 and IL-8 and defective tolerance induction in SSc B cells. In addition, the study reveals that B cells in SSc have a reduced ability to produce IL-10 when stimulated through innate immune pathways. In contrast to healthy individuals, tolerance checkpoints in SSc patients fail to suppress the emergence of B cells that produce autoantibodies with specificity to the Scl-70 antigen, a specificity strongly associated with SSc. These defects are paralleled by altered intracellular signalling and apoptosis following B cell receptor (BCR) engagement. The study provides new insights into mechanisms underlying defective B lymphocyte responses in patients with SSc and their contribution to pathology.Keywords
Funding Information
- Raynaud's and Scleroderma Association (UC5)
- Arthritis Research UK
This publication has 44 references indexed in Scilit:
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsJournal of Experimental Medicine, 2012
- Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological studyAnnals of the Rheumatic Diseases, 2010
- Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyRheumatology, 2009
- Killer B lymphocytes: the evidence and the potentialInflammation Research, 2009
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 2008
- CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced SclerodermaThe American Journal of Pathology, 2008
- TLR‐mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cellsEuropean Journal of Immunology, 2007
- B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic SclerosisThe American Journal of Pathology, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006